CORAL: Angioplasty versus medical treatment of renal artery stenosis

Atherosclerotic stenosis of the renal artery is common in the elderly population. Previous clinical trials showed no benefit with angioplasty in relation to renal function but their use for preventing cardiovascular events was still uncertain. A total of 947 patients with atherosclerotic renal artery and systolic hypertension (need two or more drugs) or renal dysfunction were randomized to medical treatment with stent angioplasty or medical treatment only. The primary end point was a composite of death from cardiovascular or renal disease, heart attack, stroke, hospitalization for heart failure or need for dialysis. At 43 months follow-up there was no significant difference in the primary endpoint between the two branches (35.1 % angioplasty versus 35.8 % medical treatment, P = .58). There were no differences between groups considering separately each component of the primary end point. There was a modest but significant reduction in blood pressure with angioplasty (medical therapy -2.3 mm Hg, angioplasty -4.4, p = 0.03).

Conclusion:

The renal artery angioplasty compared with medical treatment does not provide benefits in terms of clinical events in patients with renal artery stenosis and hypertension or renal dysfunction.

Article

Discussion

1_stephen_nicholls_slides
Stephen Nicholls
2013-11-19

Original title: Stenting and Medical Therapy for Atherosclerotic Renal-Artery Stenosis

More articles by this author

COAG Trial: Dose of warfarin and Pharmacogenetics

Observational studies identified two genes that influence the dose of warfarin (CYP2C9 and VKORC1). The clinical utility of dose adjustment by genetics has been...

ERASE: Endovascular treatment plus exercise versus exercise alone to treat claudication

Initial therapy for intermittent claudication has been historically the gear train, however, especially in recent years; the number of peripheral angioplasties has increased, proving...

RADAR AF: High-frequency ablation versus pulmonary vein isolation to treat atrial fibrillation

Atrial fibrillation is initiated by focal triggers and maintained by an atrial substrate called fractioned complex of atrial electrograms. Isolating the pulmonary veins (triggers)...

EU-PACT: Warfarin dose guided by genotype

Anticoagulation level in response to a fixed dose of warfarin is difficult to predict at the start of therapy. The CYP2C9 gene polymorphism (involved...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | Asymptomatic Severe Aortic Stenosis: What Should Be our Approach?

Approximately 3% of the population over 65 years old has aortic stenosis. Current guidelines recommend valve replacement for patients with symptoms or an ejection...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...